Conditions: Leukaemia, Lymphocytic, Chronic
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 223
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether HuMax-CD20 (ofatumumab) is effective in the treatment of patients failing both fludarabine and alemtuzumab.

Detailed description:

Arms:
arm 1: Anti-CD20 antibody therapy

Interventions: intervention 1: ofatumumab
Intervention descriptions: intervention 1: Intravenous infusion

Protocol document: